Mark T. Miedel, PhD

Research Assistant Professor, Metastatic Cancer Program Team

Mark T. Miedel, PhD

Office: W904 BST
Phone: 412-383-9893



PhD in Cell Biology and Physiology, University of Pittsburgh School of Medicine

Selective inhibition of the estrogen receptor (ER) pathway via endocrine therapy is the primary treatment option for ER-positive breast cancer. However, a major problem in the clinical treatment of ER-positive breast cancer is the development of resistance to endocrine therapies. Thus, my research is focused on identifying the mechanisms that cause resistance, and to use this information to develop novel therapeutic strategies for the treatment of endocrine-resistant metastatic breast cancer.

  1. Shi S, Luke CJ, Miedel MT, Silverman GA, Kleyman TR (2016). “Activation of the Caenorhabditis elegans degenerin channel by shear stress requires the MEC-10 subunit.” Journal of Biological Chemistry; May 4. pii: jbc.M116.718031. [Epub ahead of print]. PMID: 27189943.
  2. O'Reilly LP, Long OS, Cobanoglu MC, Benson JA, Luke CJ, Miedel MT, Hale P, Perlmutter DH, Bahar I, Silverman GA, Pak SC (2014). “A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of α1-antitrypsin deficiency.” Human Molecular Genetics 23(19): 5123-32. PMID: 24838285.
  3. Miedel MT, Zeng X, Yates NA, Silverman GA, Luke CJ (2014). “Isolation of serpin-interacting proteins in C. elegans using protein affinity purification.” Methods 68(3): 536-41. PMID: 24798811.
  4. Miedel MT, Rbaibi Y, Guerriero CJ, Colletti G, Weixel KM, Weisz OA, Kiselyov K (2008). “Membrane traffic and turnover in TRP-ML1-deficient cells: a revised model for mucolipidosis type IV pathogenesis.” Journal of Experimental Medicine 205(6):1477-90. PMID: 18504305.
  5. Miedel MT, Weixel KM, Bruns JR, Traub LM, Weisz OA (2006). “Posttranslational cleavage and adaptor protein complex-dependent trafficking of mucolipin-1.” Journal of Biological Chemistry 281(18): 12751-9. PMID: 16517607.